JP2010529196A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529196A5
JP2010529196A5 JP2010512186A JP2010512186A JP2010529196A5 JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5 JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010512186 A JP2010512186 A JP 2010512186A JP 2010529196 A5 JP2010529196 A5 JP 2010529196A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529196A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/007331 external-priority patent/WO2008156632A1/en
Publication of JP2010529196A publication Critical patent/JP2010529196A/ja
Publication of JP2010529196A5 publication Critical patent/JP2010529196A5/ja
Pending legal-status Critical Current

Links

JP2010512186A 2007-06-12 2008-06-12 アザペプチド誘導体 Pending JP2010529196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Publications (2)

Publication Number Publication Date
JP2010529196A JP2010529196A (ja) 2010-08-26
JP2010529196A5 true JP2010529196A5 (cg-RX-API-DMAC10.html) 2011-08-04

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512186A Pending JP2010529196A (ja) 2007-06-12 2008-06-12 アザペプチド誘導体

Country Status (25)

Country Link
US (4) US20090036357A1 (cg-RX-API-DMAC10.html)
EP (3) EP2116532B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010529196A (cg-RX-API-DMAC10.html)
KR (2) KR101185899B1 (cg-RX-API-DMAC10.html)
CN (2) CN101711237B (cg-RX-API-DMAC10.html)
AR (1) AR066972A1 (cg-RX-API-DMAC10.html)
AT (2) ATE447554T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008267048C1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0823520A2 (cg-RX-API-DMAC10.html)
CA (1) CA2692028C (cg-RX-API-DMAC10.html)
CO (1) CO6241121A2 (cg-RX-API-DMAC10.html)
CY (1) CY1109766T1 (cg-RX-API-DMAC10.html)
DE (1) DE602008000255D1 (cg-RX-API-DMAC10.html)
DK (1) DK2003120T3 (cg-RX-API-DMAC10.html)
ES (3) ES2395137T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20100065T1 (cg-RX-API-DMAC10.html)
MX (1) MX2009013565A (cg-RX-API-DMAC10.html)
PL (1) PL2003120T3 (cg-RX-API-DMAC10.html)
PT (1) PT2003120E (cg-RX-API-DMAC10.html)
RS (1) RS51226B (cg-RX-API-DMAC10.html)
RU (2) RU2448958C2 (cg-RX-API-DMAC10.html)
SI (1) SI2003120T1 (cg-RX-API-DMAC10.html)
TW (1) TW200908970A (cg-RX-API-DMAC10.html)
WO (1) WO2008156632A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200909079B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103899A1 (en) * 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
RS51226B (sr) 2007-06-12 2010-12-31 Concert Pharmaceuticals Inc. Derivati azapeptida kao inhibitori hiv proteaze
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
AU2010338425B2 (en) 2009-12-21 2015-07-23 Janssen Sciences Ireland Uc Degradable removable implant for the sustained release of an active compound
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的制备方法
WO2017095761A1 (en) * 2015-12-02 2017-06-08 Merck Sharp & Dohme Corp. Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
SMT202300480T1 (it) 2016-03-28 2024-01-10 Incyte Corp Composti di pirrolotriazina come inibitori di tam
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
TWI821200B (zh) 2017-09-27 2023-11-11 美商英塞特公司 Tam抑制劑之鹽
PT3813800T (pt) 2018-06-29 2025-06-06 Incyte Corp Formulações de um inibidor de axl/mer
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
AU2021230385A1 (en) 2020-03-06 2022-09-22 Incyte Corporation Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
AU2021257341A1 (en) * 2020-04-16 2022-11-17 The Medical College Of Wisconsin, Inc. Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
AU2024283382A1 (en) 2023-05-31 2025-11-13 Gilead Sciences, Inc. Anti-hiv compounds
CN116987024A (zh) * 2023-08-01 2023-11-03 浙江荣耀生物科技股份有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689976T2 (de) 1985-05-15 1995-03-16 Wellcome Found Therapeutische Nucleoside und deren Herstellung.
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
DE69331643T2 (de) 1992-12-29 2002-10-31 Abbott Laboratories, Abbott Park Zwischenprodukte zur Herstellung retroviraler proteasehemmenden Verbindungen
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
AU2959397A (en) 1996-05-31 1998-01-05 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
EP1390063B1 (en) 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
NZ530722A (en) 2001-08-31 2007-11-30 Bristol Myers Squibb Co Use of atazanavir to reduce plasma LDL and/or triclyceride levels in an HIV-infected patient
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
WO2005027855A2 (en) 2003-02-21 2005-03-31 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CN101023090B (zh) 2004-07-06 2013-03-27 雅培制药有限公司 Hiv蛋白酶抑制剂的前药
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
BRPI0518741A2 (pt) 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
RS51226B (sr) 2007-06-12 2010-12-31 Concert Pharmaceuticals Inc. Derivati azapeptida kao inhibitori hiv proteaze
US20090076097A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Similar Documents

Publication Publication Date Title
JP2010529196A5 (cg-RX-API-DMAC10.html)
JP2012111758A5 (cg-RX-API-DMAC10.html)
JP2011510079A5 (cg-RX-API-DMAC10.html)
JP2012107057A5 (cg-RX-API-DMAC10.html)
JP2006515626A5 (cg-RX-API-DMAC10.html)
JP2009535462A5 (cg-RX-API-DMAC10.html)
JP2007269812A5 (cg-RX-API-DMAC10.html)
JP2013532130A5 (cg-RX-API-DMAC10.html)
JP2009502793A5 (cg-RX-API-DMAC10.html)
JP2009545527A5 (cg-RX-API-DMAC10.html)
JP2011105738A5 (cg-RX-API-DMAC10.html)
NL301202I2 (nl) Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
JP2007522220A5 (cg-RX-API-DMAC10.html)
JP2008501714A5 (cg-RX-API-DMAC10.html)
JP2012514009A5 (cg-RX-API-DMAC10.html)
JP2006526031A5 (cg-RX-API-DMAC10.html)
JP2011519871A5 (cg-RX-API-DMAC10.html)
JP2008188757A5 (cg-RX-API-DMAC10.html)
JP2009506999A5 (cg-RX-API-DMAC10.html)
JP2010241791A5 (cg-RX-API-DMAC10.html)
JP2011037885A5 (cg-RX-API-DMAC10.html)
JP2009249685A5 (cg-RX-API-DMAC10.html)
JP2006518752A5 (cg-RX-API-DMAC10.html)
JP2011515327A5 (cg-RX-API-DMAC10.html)
JP2009504909A5 (cg-RX-API-DMAC10.html)